Mercado mundial de productos biológicos: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado                              

Los productos biológicos han adquirido un gran impulso en los últimos años, ya que se utilizan para tratar una variedad de enfermedades y dolencias, como la enfermedad de Crohn , la colitis ulcerosa, la artritis reumatoide y otras enfermedades autoinmunes. Se espera que el uso generalizado del producto impulse el crecimiento del mercado mundial de productos biológicos en los próximos años. Los productos biológicos están a la vanguardia de la investigación y respaldan los avances más recientes. Se espera que estos avances den como resultado tratamientos revolucionarios que brinden a los pacientes nuevas opciones de tratamiento. Se están desarrollando nuevos desarrollos y terapias únicas para la producción de nuevos productos biológicos, lo que indica que se anticipa que el mercado mundial de productos biológicos tendrá una perspectiva futura positiva.

Data Bridge Market Research analiza que el mercado de productos biológicos se valoró en USD 264 mil millones en 2021 y se espera que alcance los USD 596,65 mil millones para 2029, registrando una CAGR del 9,25% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

Biologics, commonly referred to as biological medications, are disease-modifying antirheumatic drugs (DMARDs) that are manufactured from live creatures or contain living organism components. Vaccines, blood, blood components, tissues, cells, allergies, genes, and recombinant proteins are among the items derived from humans, insects, microbes, animals, plants, and birds. These products regulate the development of essential proteins, alter human hormones and cells, and produce compounds that either activate or suppress the immune system. They also alter the way natural biologic intracellular and cellular activities function.

Biologics Market Dynamics

Drivers

• Rise in the prevalence of chronic diseases

The surging prevalence of chronic diseases is a major factor driving the biologics market's growth rate during the forecast period of 2022-2029. As per World Health Organization (WHO), chronic diseases kill more than 41 million people worldwide each year. The most common chronic disease, cardiovascular disease, kills 17.9 million people per year, followed by cancer, diabetes and respiratory disorders. These four groups are responsible for 80% of all chronic disease mortality. Chronic diseases have prompted the development of sophisticated diagnostics and therapeutics. Biologics are medicines that have been genetically modified to target a portion of the immune system that causes inflammation.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of biologics market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the biologics market. Additionally, sedentary lifestyle of people and surging geriatric population will result in the expansion of biologics market. Along with this, favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the biologics market growth. In addition, scientists and researchers are studying species and expression systems to improve biological products' productivity. In addition, a number of pharmaceutical companies are conducting research and development (R and D) to increase the efficacy of oral medications for rheumatoid arthritis and Crohn's disease. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the biologics market during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the biologics market. Additionally, lack of awareness about the utilization of biologics in research centers will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029. Biologics are sensitive to heat and light, due to which they require a superior refrigeration procedure that is not consistent over the world. This is estimated to obstruct the market's growth rate. .

This biologics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biologics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Biologics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Biologics Market

The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets.

On the brighter side, during the pandemic, there was a high need for biologics due to the increased COVID-19 burden, which further fuelled the market's growth rate. The National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 to develop a COVID-19 vaccine for clinical use in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is currently being developed in Wuhan, China. As a result, the COVID-19 outbreak had a positive impacted on the biologics market. Furthermore, the number of research and development activities on biologics for the treatment of COVID-19 is also increased. Additionally, the governments of various countries are also taking new initiatives for promoting the healthcare sector and ensuring the availability of biologics

Recent Development

• In November 2021, Bristol-Myers Squibb Company had received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.

Global Biologics Market Scope

The biologics market is segmented on the basis of type, drug class, therapeutic application, source, manufacturing, drug type, mode of purchase, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tumor Necrosis Factor (TNF) Inhibitor
• T-cell Inhibitor
• Selective Co-stimulation Modulators
• Interleukin-6 (IL-6) or Interleukin-17 Blocker
• Interleukin-1 (IL-1) Blocker
• B-cell Inhibitor

Drug Class

• Monoclonal Antibody
• Recombinant Insulin
• Vaccine
• Blood Factor
• Human Growth Hormone
• Erythropoietin
• Fusion Protein
• Recombinant Enzyme
• Interferon
• Colony-stimulating Factor
• Gene Therapy
• Cell Therapy
• Oligonucleotides
• Others
• Peptide
• Botulinum Toxin
• Others

Therapeutic Application

• Oncology
• Autoimmune/Immunologic Diseases
• Metabolic Disorders
• Ophthalmic Diseases
• Respiratory Disorders
• Inflammatory Bowel Diseases (IBDs)
• Neurological Disorders
• Cardiovascular Diseases (CVDs)
• Musculoskeletal Disorders (MSDs)
• Infectious Diseases
• Others

Source

• Microbial
• Mammalian
• Others

Manufacturing

• Outsourced
• In-House

Drug Type

• Branded Drugs
• Generic Drugs

Mode of Purchase

• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Dosage Form

• Injection
• Tablets
• Others

Route of Administration

• Parenteral
• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Biologics Market Regional Analysis/Insights

Se analiza el mercado de productos biológicos y se proporcionan información y tendencias del tamaño del mercado por país, tipo de fármaco, clase de fármaco, aplicación terapéutica, fuente, fabricación, tipo de fármaco, modo de compra, forma de dosificación, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.

Los países cubiertos en el informe del mercado de productos biológicos son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur.

América del Norte domina el mercado de productos biológicos en términos de participación de mercado e ingresos de mercado y seguirá fortaleciendo su dominio durante el período de pronóstico. Esto se debe a la presencia de actores clave importantes y al aumento del gasto en atención médica que impulsará aún más la tasa de crecimiento del mercado en esta región. Además, el aumento de las colaboraciones estratégicas para el desarrollo de tratamientos biológicos para enfermedades agudas y crónicas impulsará aún más la tasa de crecimiento del mercado en esta región.

Se espera que Asia-Pacífico crezca durante el período de pronóstico de 2022 a 2029 debido a la creciente prevalencia de artritis reumatoide, trastornos renales y hepáticos en esta región. Además, el desarrollo de la infraestructura de atención médica y el aumento de la población geriátrica impulsarán aún más la tasa de crecimiento del mercado en esta región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado de los productos biológicos

El panorama competitivo del mercado de productos biológicos proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de productos biológicos.

Algunos de los principales actores que operan en el mercado de productos biológicos son:

• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Boehringer Ingelheim International GmbH (Alemania)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Eli Lilly and Company (Estados Unidos)
• Allergan (Irlanda)
• Abbott (Estados Unidos)
• LEO Pharma A/S (Dinamarca)
• Industrias farmacéuticas Sun Ltd. (India)
• Aurobindo Pharma (India)
• Lupino (India)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Zydus Cadila (India)

SKU-56794